The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; Report of a prospective double blind placebo controlled trial

Medical Microbiology and Immunology

Volumn 186, Issue 1, 1997, Pages 31-36

  Skinner, G R B ^a   Turyk, M E ^b   Benson, C A ^b   Wilbanks, G D ^b   Heseltine, P ^c   Galpin, J ^d   Kaufman, R ^b   Goldberg, L ^e   Hartley, C E ^a   Buchan, A ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b RUSH MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Texas Medical Center ^*  (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; Herpes simplex virus; Intracellular; Subunit; Vaccine

Indexed keywords

HERPES SIMPLEX VACCINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 1; HUMAN; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; UNITED STATES; VACCINATION; VIRUS CELL TRANSFORMATION;

ADULT; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HUMANS; MALE; PROSPECTIVE STUDIES; RECURRENCE; VACCINATION; VIRAL VACCINES;

EID: 8544253234     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004300050043     Document Type: Article

References (29)

1. Blank H, Haines HG (1973) Experimental human reinfection with herpes simplex virus. J Invest Dermatol 61:223-225
2. Bruckner R (1970) Erste persönliche Erfahrungen mit dem Vaccin antiherpetique "Diamant" Ophthalmologica 161:104-107
3. Burke RL, Goldbeck C, Ng P, Stanbery L, Ott G, VanNest G (1994) The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 170: 1110-1119
4. Cappel R, Sprecher S, DeCuyper F, DeBraekeleer J (1985) Clinical efficacy of a herpes simplex subunit vaccine. J Med Virol 16:137-145
5. Corey L, Spear PG (1986) Infections with herpes simplex viruses, II. N Engl J Med 314:749-757
6. Corey L, Spear PG (1986) Infections with herpes simplex viruses, I. N Engl J Med 314:686-691
7. Corey L, Reeves WC, Holmes KK (1978) Cellular immune response in genital herpes simplex virus infection. N Eng J Med 299:986-991
8. Henocq E, Rudder J de, Maurin J, Lepine P (1964) Essai de therapeutique de l'herpes recidivant par un vaccin prepare en culture cellulaire et inactive par les rayons ultraviolets. II. Essais Cliniques. Sem Hop 40:1474-1480
9. Kaplowitz LG, Baker D, Gelb L, et al (1991) Prolonged continuous Acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. JAMA 265: 747-751
10. Kern AB, Schiff BL (1964) Vaccine therapy in recurrent herpes simplex. Dermatologica 89: 844-845
11. Kutinova L, Benda R, Kalos Z, et al (1988) Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine 6:223-228
12. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L (1987) Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 316:1444-1449
13. Lopez C, O'Reilly RJ (1977) Cell-mediated immune responses in recurrent herpesvirus infections. I. Lymphocyte proliferation assay. J Immunol 118:895-902
14. Mertz GJ, Jones CC, Mills J et al (1988) Long-term Acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. JAMA 260: 201-206
15. Mullin WB; cited in Hull RN, Peck FB (1967) Vaccination against herpesvirus infections. Proceedings of 1st Conference on Vaccines Against Viral and Rickettsial Diseases in Man Scientific Publication 147. Pan American Health Organisation, Washington, DC, p 266-275
16. Muniu EM, Durham J, Shariff D, et al. (1987) Antibody reactivity in 15 subjects following immunisation with Skinner HSV vaccine. Med Microbiol Immunol 176:315-327
17. Nasemann T (1970) Neuere Behandlungsmethoden unterschiedlicher Herpes simplex Infektionen. Arch Klin Exp Dermatol 237: 234-237
18. Russell WC (1962) A sensitive and precise plaque assay for herpesvirus. Nature 195:1028-1029
19. Skinner GRB, Thoulness, ME, Edwards J, Trueman S, Gibbs AJ (1976) Serological relatedness of herpes simplex viruses: type-specificity of antibody response. Immunology 31:481-494
20. -) MRC toward prevention of herpes genitalis in human subjects. Br J Vener Dis 58:381-386
21. -) MRC in a Rhesus monkey model towards protection against primary herpes genitalis. Br J Exp Pathol 63:378-382
22. Skinner GRB, Fink C, Melling J, et al (1992) Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis. Med Microbiol Immunol 180:305-320
23. Skinner GRB, Davies JA, Ahmad A et al (1996) An outbreak of herpes rugbiorum managed by vaccination of players and sociosexual contacts J Infect 33:163-167
24. Soltz-Szots J (1971) Die Behandlung des resiverenden Herpes simplex. Z Haut Geschlechtskr 46:267-272
25. Stanberry LR, Burke RL, Myers MG (1988) Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J Infect Dis 157:156-163
26. Strauss SE, Corey L, Burke RL, et al (1994) Placebo-controlled trial of vaccination with recombinam glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463
27. Von Rodovsky J, Dbaly V, Benda R (1971) Präventivbehandlung des reziverended Herpes mit einer aus Kaninchennierenzellen hergestellt Formolvakine. Dermatol Monatsschr 157:701-708
28. Weitgasse H (1977) Kontrollierte Klinische Studie mit den Herpes Antigenen Lupidon H und Lupidon G. Z Hautkr 52: 625-628
29. Woodman CBJ, Buchan A, Fuller A, et al (1983) The efficacy of vaccine AcNFU1 (S )MRC5 administered following an initial clinical episode towards prevention of herpes genitalis. Br J Vener Dis 59:311-313